Crescent Biopharma, Inc. Tangible Net Worth Ratio
Crescent Biopharma, Inc. tangible net worth ratio. Crescent Biopharma, Inc. (CBIO) has a Tangible Net Worth Ratio of 100.0% as of June 2026. This metric is calculated by deducting intangible assets ($0.00) from net assets ($163.25 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See debt-free asset ratio of Crescent Biopharma, Inc. to measure how much of total assets are equity-financed.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Tangible Net Worth Ratio of Crescent Biopharma, Inc. (2011–2025)
Tangible net worth ratio of Crescent Biopharma, Inc. from 2011 to 2025. This chart shows how Crescent Biopharma, Inc.'s Tangible Net Worth Ratio has changed across 14 annual periods from 2011 to 2025. As of June 2026, the ratio stands at 100.0%, reflecting net assets of $163.25 Million with intangible assets of $0.00 USD. See Crescent Biopharma, Inc. current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Crescent Biopharma, Inc. Tangible Net Worth Ratio by Year (2011–2025)
Crescent Biopharma, Inc. tangible net worth ratio by year from 2011 to 2025. The table below presents the year-by-year Tangible Net Worth Ratio for Crescent Biopharma, Inc. from 2011 to 2025, covering 14 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see Crescent Biopharma, Inc. market capitalisation.
| Year | Tangible NW Ratio | Net Assets (USD) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 97.7% | $203.01 Million | $4.73 Million | $240.29 Million | ▼ -2.3 pp |
| 2023 | 100.0% | $38.41 Million | $0.00 | $45.32 Million | ▲ +0.0 pp |
| 2022 | 100.0% | $42.93 Million | $0.00 | $51.81 Million | ▲ +0.0 pp |
| 2021 | 100.0% | $81.60 Million | $0.00 | $94.35 Million | ▲ +0.0 pp |
| 2020 | 100.0% | $128.22 Million | $0.00 | $142.83 Million | ▲ +0.0 pp |
| 2019 | 100.0% | $154.20 Million | $0.00 | $167.97 Million | ▲ +0.0 pp |
| 2018 | 100.0% | $205.46 Million | $0.00 | $214.84 Million | ▲ +0.0 pp |
| 2017 | 100.0% | $119.70 Million | $0.00 | $128.58 Million | ▲ +0.0 pp |
| 2016 | 100.0% | $35.30 Million | $0.00 | $42.39 Million | ▲ +0.0 pp |
| 2015 | 100.0% | $40.47 Million | $0.00 | $48.46 Million | ▲ +0.0 pp |
| 2014 | 100.0% | $50.80 Million | $0.00 | $57.26 Million | ▲ +0.0 pp |
| 2013 | 100.0% | $2.91 Million | $0.00 | $5.28 Million | ▲ +0.0 pp |
| 2012 | 100.0% | $12.53 Million | $0.00 | $18.42 Million | ▲ +0.0 pp |
| 2011 | 100.0% | $8.46 Million | $0.00 | $28.91 Million | — |